Steroid profiling as a biomarker tool in the diagnosis and monitoring of adrenal tumours

类固醇分析作为诊断和监测肾上腺肿瘤的生物标志物工具

• 批准号: G0801473/1
• 负责人: Wiebke Arlt
• 金额: $ 92.65万
• 依托单位: University of Birmingham
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2009
• 资助国家: 英国
• 起止时间: 2009 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0801473%2F1
• 关键词: Steroid; profiling; biomarker; tool; diagnosis

Adrenal tumours are common, affecting 1-2% of the general population. However, these tumours become more common with ageing and 3% of 40-year-olds and 10% of 70-year-olds have an adrenal tumour, many of them without knowing it. The majority of adrenal tumours are discovered incidentally, mostly following an imaging procedure like CT scanning arranged for other reasons than suspected adrenal disease. Once discovered, nodules in the adrenal need to be carefully evaluated as they may overproduce hormones with a potentially detrimental effect on health and, importantly, they could be malignant, either arising from the adrenal itself or representing metastases of other malignancies. Currently we use different imaging procedures and blood tests in the work-up of patients with adrenal tumours, but this is not always informative enough and it is often difficult to decide whether an adrenal tumour is benign or malignant. We have developed a biomarker tool that measures the excretion of steroid hormones deriving from the adrenal gland in urine samples provided by adrenal tumour patients. Preliminary results indicate that there are highly significant differences in steroid hormone excretion between benign and malignant adrenal tumours. In this proposal we will validate this method by the prospective analysis of a large number of urine samples from adrenal tumour patients by our measurement technique, called gas chromatography/mass spectrometry (GC/MS). Measurement results will be analyzed in collaboration with mathematicians who will help us to identify those hormones that will inform us best about the differences between benign and malignant tumours. Use of a related technology method - liquid chromatography/ mass spectrometry, LC/MS/MS ? will then be employed for the rapid measurement of steroids, which will help to integrate our biomarker tool into routine clinical practice. Patient recruitment to this study will be driven by national and international collaborative networks including the European Network for the Study of Adrenal Tumours (ENS@T), which will ensure that we can recruit the necessary patient number during the study lifetime. This proposal links a team of experienced researchers from different disciplines, which will ensure that we succeed in improving the care of patients with adrenal tumours.

肾上腺肿瘤是常见的，影响1-2%的总人口。然而，随着年龄的增长，这些肿瘤变得越来越常见，40岁的人中有3%和70岁的人中有10%患有肾上腺肿瘤，其中许多人并不知道。大多数肾上腺肿瘤是偶然发现的，大多数是在成像程序后发现的，如CT扫描，而不是怀疑肾上腺疾病。一旦发现，肾上腺中的结节需要仔细评估，因为它们可能过度产生激素，对健康有潜在的不利影响，重要的是，它们可能是恶性的，无论是由肾上腺本身引起的还是代表其他恶性肿瘤的转移。目前，我们在肾上腺肿瘤患者的检查中使用不同的成像程序和血液检查，但这并不总是提供足够的信息，并且通常难以确定肾上腺肿瘤是良性还是恶性。我们已经开发了一种生物标志物工具，其测量肾上腺肿瘤患者提供的尿液样本中源自肾上腺的类固醇激素的排泄。初步结果表明，良性和恶性肾上腺肿瘤之间的类固醇激素分泌有非常显着的差异。在本提案中，我们将验证这种方法的前瞻性分析大量的尿液样本肾上腺肿瘤患者通过我们的测量技术，称为气相色谱/质谱（GC/MS）。测量结果将与数学家合作进行分析，数学家将帮助我们识别那些激素，这些激素将最好地告知我们良性和恶性肿瘤之间的差异。使用相关技术方法-液相色谱/质谱法，LC/MS/MS？然后将用于快速测量类固醇，这将有助于将我们的生物标志物工具整合到常规临床实践中。本研究的患者招募将由国家和国际合作网络（包括欧洲肾上腺肿瘤研究网络（ENS@T））推动，这将确保我们能够在研究生命周期内招募必要的患者数量。该提案将来自不同学科的经验丰富的研究人员团队联系起来，这将确保我们成功地改善肾上腺肿瘤患者的护理。